XML 39 R29.htm IDEA: XBRL DOCUMENT v3.21.1
Financial Instruments and Fair Value Measurements (Tables)
 3 Months Ended
Mar. 26, 2021
Fair Value Disclosures [Abstract]  
Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis
The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:

March 26,
2021
Quoted Prices in Active Markets for Identical Assets
(Level 1)
Significant Other Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Assets:
Debt and equity securities held in rabbi trusts
$32.9 $23.1 $9.8 $— 
Equity securities
39.5 39.5 — — 
$72.4 $62.6 $9.8 $— 
Liabilities:
Deferred compensation liabilities
$32.1 $— $32.1 $— 
Contingent consideration and acquired contingent liabilities
23.9 — — 23.9 

$56.0 $— $32.1 $23.9 
December 25,
2020
Quoted Prices in Active Markets for Identical Assets
(Level 1)
Significant Other Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Assets:
Debt and equity securities held in rabbi trusts$33.0 $23.5 $9.5 $— 
Equity securities31.1 31.1 — — 
$64.1 $54.6 $9.5 $— 
Liabilities:
Deferred compensation liabilities$38.0 $— $38.0 $— 
Contingent consideration and acquired contingent liabilities34.7 — — 34.7 
$72.7 $— $38.0 $34.7 
Schedule of Reconciliation of Changes in Fair Value of Contingent Liabilities The following table summarizes the activity for contingent consideration:
Balance as of December 25, 2020$34.7 
Fair value adjustments
(10.8)
Balance as of March 26, 2021$23.9 
Schedule of Carrying Amount and Fair Value of Long-term Debt The following table presents the carrying values and estimated fair values of the Company's debt as of the end of each period:
March 26, 2021December 25, 2020
Carrying
Value		Fair
Value		Carrying
Value		Fair
Value
Level 1:
5.75% senior notes due August 2022$610.3 $407.7 $610.3 $191.2 
4.75% senior notes due April 2023133.7 26.2 133.7 11.1 
5.625% senior notes due October 2023514.7 337.1 514.7 158.9 
5.50% senior notes due April 2025387.2 258.1 387.2 115.4 
10.00% first lien senior notes due April 2025495.0 553.4 495.0 528.4 
10.00% second lien senior notes due April 2025322.9 321.8 322.9 279.0 
Revolving credit facility900.0 900.0 900.0 900.0 
Level 2:
9.50% debentures due May 202210.4 4.2 10.4 4.2 
8.00% debentures due March 20234.4 1.3 4.4 1.3 
Term loan due September 20241,411.2 1,394.7 1,505.2 1,386.9 
Term loan due February 2025374.6 369.8 399.5 367.9 
Total Debt$5,164.4 $4,574.3 $5,283.3 $3,944.3 
Schedules of Concentration of Risk
The following table shows net sales attributable to distributors that accounted for 10.0% or more of the Company's total segment net sales:
Three Months Ended
March 26,
2021		March 27,
2020
CuraScript, Inc.
24.9 %24.6 %

The following table shows accounts receivable attributable to distributors that accounted for 10.0% or more of the Company's gross accounts receivable at the end of each period:
March 26,
2021		December 25,
2020
AmerisourceBergen Corporation
33.2 %33.6 %
McKesson Corporation
15.9 18.2 
CuraScript, Inc.
11.1 *
*Accounts receivable attributable to this distributor was less than 10.0% of total gross accounts receivable at the end of the respective period presented above.

The following table shows net sales attributable to products that accounted for 10.0% or more of the Company's total segment net sales:
Three Months Ended
March 26,
2021		March 27,
2020
Acthar Gel23.1 %25.2 %
INOmax24.0 21.3 
Ofirmev*11.2 
Therakos12.0 *
*Net sales attributable to these products were less than 10.0% of total net sales during the respective periods presented above.